Citizens JMP reiterates Market Outperform rating on Axon Enterprise stock

Axon Enterprise (NASDAQ:AXON) reported robust Q2 2025 results, with non-GAAP EPS of $2.12 and revenue of $668.5 million significantly surpassing analyst consensus, alongside a 33% year-over-year revenue increase and strong adjusted EBITDA. The company saw $150 million in bookings for its new AI Era Plan, contributing to its operational strength and 3.9% aftermarket stock gain. This performance reinforces Citizens JMP's Outperform rating, with Axon's stock up 30% year-to-date, significantly outperforming the Russell 3000.

Analysis

Axon Enterprise (AXON) delivered a robust second-quarter 2025 performance, significantly exceeding market expectations across key metrics. The company reported non-GAAP earnings per share of $2.12, substantially outperforming the consensus estimate of $1.44, alongside revenue of $668.5 million, which represented a 33% year-over-year increase and surpassed the forecast of $641.0 million. Adjusted EBITDA growth was also strong at 38% year-over-year to $171.6 million. This financial strength appears to be driven by successful product innovation and market adoption, as evidenced by the company securing nearly $150 million in bookings for its new "AI Era Plan" in Q2 alone, with new product categories accounting for over 30% of total bookings. The market reacted positively, with the stock rising approximately 3.9% in aftermarket trading. This strong quarter reinforces Axon's significant year-to-date outperformance, with its 30% gain far outpacing the Russell 3000's 7.3% increase, and supports the reiterated Market Outperform rating and $825 price target from Citizens JMP.

Key Decisions for Investors

• The significant earnings beat and strong revenue growth, fueled by new AI-related products, reinforce the company's growth trajectory, suggesting that current long positions are well-justified and any price weakness could be viewed as an attractive entry point.
• Investors should closely monitor the continued adoption rate and booking momentum of Axon's 'AI Era Plan' and other new product categories in subsequent quarters, as this is a primary driver of the current valuation premium and growth thesis.
• Considering the stock's substantial 30% year-to-date outperformance, investors should assess whether the strong Q2 results and positive outlook are fully priced in, and remain vigilant for any shifts in execution that could impact the high valuation.